Origin House Announces Sequential Revenue Growth of 89% for the Third Quarter 2018

• Record Q3 revenue of $6.6 million; growth of 89% over Q2 2018 and 790% over Q3 2017.
• On October 18, 2018, closed the acquisition of RVR Distribution ("RVR"), including five licensed distribution and manufacturing facilities across California, and several of the state's top independent branded products.
• Distribution platform reached 486 licensed California dispensaries as of September 30, 2018¹.
• Advancing acquisition of 180 Smoke to provide California brand partners with rapid access to the Canadian market.
• Closed the acquisition of premium Sonoma County craft cannabis producer, FloraCal^® Farms.
• Continued to generate shareholder value through the monetization of non-core assets; +487%² return on invested capital.
• Strong cash position of $75.3 million as of September 30, 2018 to continue executing our vision.

OTTAWA, Nov. 28, 2018 /CNW/ - Origin House Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) ("Origin House" or the "Company"), a leading North American cannabis products and brands company, announced today the Company's financial results for the three and nine-month periods ended September 30, 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated. Origin House's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Marc Lustig, CEO of Origin House, commented, "Last quarter, we stated that after a substantial period of building a foundation, Origin House was at the beginning of a multi-period, sustainable acceleration in revenue growth. Year-to-date, we generated record revenue, completed four transformational acquisitions and are well-capitalized to continue growing. We expect to continue delivering strong revenue growth throughout Q4, 2019 and beyond, as RVR and 180 Smoke are integrated and as we further leverage our brand development and support platform. Our view is that the next 12 months are going to be critical in determining the winners in the cannabis space. Origin House is positioned as a premier operator in the largest and most dynamic cannabis market in the world and we believe we are just at the beginning of our growth curve. We expect this platform to become increasingly difficult to replicate and therefore increasingly valuable for our shareholders as our financial results accelerate, as well as for other operators in the cannabis space that need to be in California."

"One year ago, we unveiled our ambitions to the public. In that period, Origin House has already created a proven track record of identifying break-out brands, partnering with them and selling to customers in a competitive marketplace to drive mutual success," said Afzal Hasan, President and General Counsel of Origin House. "The financial results we generated in Q2 and Q3 are representative of just the initial framework of a model primed for growth. We have already shown some early success in supporting the growth of some of the largest independent brands in California, like Lowell's Smokes and King's Garden. Our growing suite of brand development and support solutions, including financing, allows us to structure innovative, revenue driving deals with other emerging brands, like we have done with Henry's Original, Pacific Remedy and Utopia. These deals are the first in an extensive pipeline of brand partnerships that we are now executing on. Investing in our partners enables them to scale and realize their aspirations while providing us with sizable upside and limited risk."

Mr. Hasan added, "We intend to leverage the foundation we have built in California to not just drive revenue growth, but also to grow and hone our employee base for deployment into new markets. The institutional knowledge we are developing from operating in the largest and most culturally significant cannabis market in the world has already taught us valuable lessons that we are carrying over to Canada. We are taking a calculated approach involving the use of a profitable and rapidly growing retail platform, 180 Smoke, for direct to consumer marketing by our brand partners. We are excited about this prospect, and are actively pursuing strategies for expansion of our brand partners into other regulated markets around the globe."

1)	Internal source: based on rolling 6-month data
2)	Includes the sale of: Anandia Laboratories Inc.; and Wagner Dimas Inc. (equity interest and license)

Financial Highlights – Q3 – 2018

The following are the major financial highlights of Origin House's operating results for the three months ended September 30, 2018, compared to the three months ended September 30, 2017: 

• revenues were $6.6 million as compared to $744,302, an increase of 790%;
  
  
• gross margin was $298,619 as compared $128,010, an increase of 133%;
  
  
• operating expenses were $10.1 million as compared to $2.8 million, an increase of 261%;
  
  
• net loss of $7.5 million as compared to $3.3 million, an increase of 128%;
  
  
• net loss per basic and dilutive shares of $0.12 as compared to $0.08; and
  
  
• adjusted EBITDA loss of $4.5 million as compared to a loss of $1.8 million.

The following is a summary of key balance sheet totals as at September 30, 2018, compared to December 31, 2017.

• cash was $75.3 million as compared to $4.5 million an increase of 1,565%;
  
  
• total assets of $220.2 million as compared to $46.1 million, an increase of 377%;
  
  
• current assets of $90.8 million as compared to $7.9 million, an increase of 1,043%;
  
  
• current liabilities of $27.2 million as compared to $2.1 million, an increase of 1,172%; and
  
  
• long-term debt of $28.2 million as compared to $2.3 million, an increase of 1,147%.
  

Recent Developments

For a more comprehensive overview of these recent developments, please refer to Origin House's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2018.

• On October 3, 2018, Origin House signed a definitive agreement with Australis whereby Australis will purchase 2,200,000 common shares in the capital of Wagner Dimas from Cannroy Delaware Inc. ("Cannroy Delaware"), a wholly-owned subsidiary of Origin House. The sale closed on November 19, 2018.
  
  
• On October 3, 2018, Trichome, entered into an agreement with 22 Capital to complete a transaction that will result in a reverse take-over of 22 Capital by the shareholders of Trichome. If completed, the resulting issuer will be listed on the TSX Venture Exchange.
  
  
• On October 18, 2018, Origin House closed the previously announced acquisition of RVR Distribution ("RVR"). Upon closing the acquisition, Origin House gained legal control of RVR, however, the Company had control under IFRS 10 from September 1, 2018. Additionally, Ted Simpkins, Co-Founder and CEO of RVR joined the Origin House Board of Directors, effective October 18, 2018.
  
  
• On October 22, 2018, CannaRoyalty Corp. registered "Origin House" as a business name and began to conduct business under the Origin House brand.
  
  
• On October 23, 2018, the Company's changed its ticker symbol from "CRZ" to "OH" on the Canadian Securities Exchange and from "CNNRF" to "ORHOF" on the OTCQX market in the United States.
  
  
• On November 22, 2018, Origin House began partnering with Mendocino Cannabis Brand, Henry's Original, to offer strategic investment and innovative brand acceleration.
  
  
• On November 23, 2018, the Company accelerated the expiry of all outstanding common share purchase warrants to December 14, 2018. If all warrants are exercised they will generate proceeds of $10.6 million for Origin House.
  

Results of Operations (Summary)
The following tables set forth consolidated statements of financial information for the three and nine-month periods ending September 30, 2018, and September 30, 2017. For further information regarding the Company's financial results for these periods, please refer to the Company's Management's Discussion and Analysis for the periods ended September 30, 2018 and September 30, 2017 and the Company's Financial Statements for the periods ended September 30, 2018, published on Origin House's issuer profile on SEDAR at www.sedar.com and the Company's website at www.Origin House.com.

	September  30, 2018		December 31, 2017		Change
Selected statement of financial position data
Cash and cash equivalents	$	75,282,348	$	4,522,644	$	70,759,704
Working capital	63,658,301		5,813,705		57,844,596
Total investments (1)	10,874,921		26,674,288		(15,799,367)
Total assets	220,204,036		46,139,757		174,064,279
Long term and convertible debt	28,171,149		2,258,467		25,912,682
Purchase consideration payable	2,136,274		-		2,136,274
Shareholders' equity	147,220,545		40,468,344		106,752,201
Dividends, per share	-		-		-

(1) This represents the sum of investments, royalty investments, and interests in equity method

	Three months ended September 30				Nine months ended September 30
	2018		2017		2018		2017
Consolidated Statements of Net Loss
Revenue	$	6,623,998	$	744,302	$	10,778,901	$	2,005,570
Gross margin, excluding fair value items	508,396		128,010		1,299,701		794,164
Operating expenses	10,064,130		2,834,939		20,824,360		8,629,385
Loss from operations	(9,765,511)		(2,706,929)		(19,734,436)		(7,835,221)
Net loss	(7,502,098)		(3,295,477)		(2,858,083)		(7,816,773)
Other income (expense)	2,015,184		(662,197)		16,737,179		(212,254)
Total comprehensive loss	(9,265,872)		(3,618,961)		(3,377,788)		(8,677,392)
Net loss per common share - basic & diluted	(0.12)		(0.08)		(0.05)		(0.19)
Weighted average common shares - basic & diluted	57,621,347		42,156,344		51,634,188		40,961,436

Revenue by Type
	Three months ended September 30				Nine months ended September 30
	2018		2017		2018		2017
Product sales	$	6,250,992	$	298,866	$	9,446,382	$	703,193
Services	69,760		41,451		737,921		314,594
Royalties	108,306		385,001		364,553		928,095
Interest income	194,940		18,984		230,045		59,688
Total	$	6,623,998	$	744,302	$	10,778,901	$	2,005,570

Cost of Sales by Revenue Type
	Three months ended September 30				Nine months ended September 30
	2018		2017		2018		2017
Cost of product sales	$	5,900,572	$	327,986	$	8,354,623	$	688,917
Cost of services	35,000		23,961		304,024		61,656
Cost of royalties	180,030		264,345		820,553		460,833
Total	$	6,115,602	$	616,292	$	9,479,200	$	1,211,406

Gross Profit by Revenue Type
	Three months ended September 30				Nine months ended September 30
	2018		2017		2018		2017
Products	$	350,420	$	(29,120)	$	1,091,759	$	14,276
Services	34,760		17,490		433,897		252,938
Royalties	(71,724)		120,656		(456,000)		467,262
Interest	194,940		18,984		230,045		59,688
Total	$	508,396	$	128,010	$	1,299,701	$	794,164

Gross Margin by Revenue Type
	Three months ended September 30		Nine months ended September 30
	2018	2017	2018	2017
Products	6%	(10%)	12%	2%
Services	50%	42%	59%	80%
Royalties	(66%)	31%	(125%)	50%
Interest	100%	100%	100%	100%
All Types	8%	17%	12%	40%

Operating Expenses
	Three months ended September 30					Nine months ended September 30
	2018		2017		Change	2018		2017		Change
Sales and marketing	$	1,947,706	$	422,362	361%	$	3,535,796	$	1,068,443	231%
Research and product development	211,469		275,839		(23%)	472,371		900,932		(48%)
General and administrative	6,457,990		1,943,675		232%	14,665,054		6,058,597		142%
Amortization of intangibles	1,446,965		193,063		649%	2,151,139		601,413		258%
Total	$	10,064,130	$	2,834,939	255%	$	20,824,360	$	8,629,385	141%

Adjusted EBITDA^1
	Three months ended September 30				Nine months ended September 30
	2018		2017		2018		2017
Add (Subtract)
Net loss for the period	$	(7,502,098)	$	(3,295,477)	$	(2,858,083)	$	(7,816,773)
Depreciation of property and equipment	174,274		46,532		300,072		137,730
Amortization of intangible assets	1,446,965		193,063		2,151,139		601,413
Amortization of royalty investments	180,030		245,753		820,553		411,145
Interest expense	1,185,257		85,935		1,846,540		122,054
Interest income	(194,940)		(18,984)		(230,045)		(59,688)
Current income taxes	191,258		-		307,590		-
Deferred income tax recovery	(439,487)		(73,649)		(446,764)		(230,702)
EBITDA	(4,958,741)		(2,816,827)		1,891,002		(6,834,821)
Listing expense	-		-		-		38,193
Penalties from non-completion of transactions	-		(6,498)		-		214,555
Gain on sale of equipment	-		(3,000)		-		(91,674)
Gain on settlement of interests at acquisition	(1,098,374)		-		(1,098,374)		-
Recovery on Achelois Inventory	-		-		(441,370)		-
Share based compensation	1,143,050		695,144		4,222,563		2,499,356
Unrealized loss on embedded derivatives	-		369,036		-		369,036
Realized fair value amounts included in inventory sold	1,161,471		-		1,161,471		-
Unrealized fair value gain on growth of biological assets	(951,694)		-		(951,694)		-
Transaction costs on acquisitions	254,714		-		536,840		-
TOTAL ADJUSTED EBITDA	$	(4,449,574)	$	(1,762,145)	$	5,320,438	$	(4,937,462)

¹ EBITDA and Adjusted EBITDA are non-GAAP financial measures and accordingly they are not earnings measures recognized by IFRS and do not carry standard prescribed significance. Moreover, our method for calculating Adjusted EBITDA may differ from that used by other companies using the same designation.  Accordingly, we caution readers that Adjusted EBITDA should not be substituted for determining net income (loss) as an indicator of operating results or as a substitute for cash flows from operating and investing activities.

Share Capital

The Company's authorized share capital is an unlimited number of common shares of which 55,202,247 were issued and outstanding as at September 30, 2018 (December 31, 2017 – 43,898,445 common shares). The Company has issued 3,487,832 RSUs that have not been exercised as at September 30, 2018 including 2,357,837 that have vested (December 31, 2017 – 4,153,150 including 1,933,587 that had vested).  As of September 30, 2018, there are share purchase warrants and broker warrants outstanding that can potentially be converted to 3,549,765 shares (December 31, 2017 – 4,112,712).   The Company has issued 930,500 share options that have not been exercised as at September 30, 2018 including 270,750 that have vested (December 31, 2017 – 850,000 including 212,500 that had vested).

Conference Call

Origin House will host a conference call on, Wednesday, November 28, 2018 at 8:30 a.m. (Eastern Time) to discuss its 2018 third quarter financial results. The call will be chaired by Marc Lustig, Chief Executive Officer, Afzal Hasan, President and General Counsel and François Perrault, Chief Financial Officer.

	Participant Dial-in	Webcast	Reference Number
Conference Call	416-764-8688 or 1-888-390-0546	https://bit.ly/2FuLajf
Replay (available for 2 weeks)	416-764-8677 or 1-888-390-0541		543806

About Origin House

Origin House is a growing cannabis products and brands company operating across key markets in the U.S. and Canada, with a strategic focus on becoming a preeminent global house of cannabis brands. The Company's foundation is in California, the world's largest regulated cannabis market where it has delivered over 130 branded cannabis products to the majority of licensed dispensaries. Origin House's brand development platform is operated out of five licensed facilities located across California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners. The Company is actively developing infrastructure to support the proliferation of its brands internationally, initially in Canada, through its pending acquisition of Canadian retailer 180 Smoke. Origin House's shares trade on the CSE under the symbol "OH" and on the OTCQX under the symbol "ORHOF". Origin House is the registered business name of Origin House Corp. For more information, visit www.originhouse.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Origin House's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements relating to timing for the Company's stock symbol change, the execution of the Company's strategy, including Phases I, II and III of the Company's business, the Company's timing and process for expansion in Canada and globally, timing for the Company's acquisition of 180 Smoke, new opportunities, future growth and other statements.

Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under US federal law; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims any intention or obligation to update or revise such information, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

Condensed Interim Consolidated Statements of Net Income (loss) (Unaudited)
In Canadian dollars

(UNAUDITED)		Three months ended September 30				Nine months ended September 30
		2018		2017		2018		2017
Revenue		$	6,623,998	$	744,302	$	10,778,901	$	2,005,570
Cost of sales		(6,115,602)		(616,292)		(9,479,200)		(1,211,406)
Gross margin, excluding fair value items		508,396		128,010		1,299,701		794,164
Realized fair value amounts of inventory sold		(1,161,471)		-		(1,161,471)		-
Unrealized fair value gain on growth of biological assets		951,694		-		951,694		-
Gross margin		298,619		128,010		1,089,924		794,164
Operating expenses
Sales and marketing		1,947,706		422,362		3,535,796		1,068,443
Research and product development		211,469		275,839		472,371		900,932
General and administrative		6,457,990		1,943,675		14,665,054		6,058,597
Amortization of brands and technologies		1,446,965		193,063		2,151,139		601,413
Loss from operations		(9,765,511)		(2,706,929)		(19,734,436)		(7,835,221)
Other income (expenses)
Gain (loss) on investments		(2,802,373)		-		12,762,704		-
Gain on the sale of licensed technology		4,196,477		-		4,196,477		-
Fair value gain on warrants		104,344		-		104,344		-
Recovery of convertible notes receivable		379,572		-		4,100		-
Profit (loss) from equity accounted investees, net of tax		10,106		(137,093)		168,664		706,821
Gain on settlement of interests at acquisition		1,098,374		-		1,098,374		-
Foreign exchange gain (loss)		213,941		(79,631)		249,056		(266,911)
Interest expense		(1,185,257)		(85,935)		(1,846,540)		(122,054)
Penalties for non-completion of share swap transaction		-		6,498		-		(214,555)
Unrealized loss on embedded derivatives		-		(369,036)		-		(369,036)
Listing expense		-		-		-		(38,193)
Gain on disposal of equipment		-		3,000		-		91,674
Interest income		-		-		-		-
Net loss before tax		(7,750,327)		(3,369,126)		(2,997,257)		(8,047,475)
Current tax expense		(191,258)		-		(307,590)		-
Deferred tax recovery		439,487		73,649		446,764		230,702
Net loss for the period		$	(7,502,098)	$	(3,295,477)	$	(2,858,083)	$	(7,816,773)
Net loss per common share - basic & diluted		(0.12)		(0.08)		(0.05)		(0.19)
Net loss per common share - diluted		(0.13)		(0.08)		(0.05)		(0.19)
Weighted average number of common shares outstanding - basic & diluted		57,621,347		42,156,344		51,634,188		40,961,436
Weighted average number of common shares outstanding  - diluted		54,150,686		42,156,344		50,464,588		40,961,436
Total net loss for the period attributable to:
Owners of the company		(7,179,771)		(3,286,719)		(2,608,647)		(7,780,398)
Attributable to non-controlling interest		(322,327)		(8,758)		(249,436)		(36,375)
		$	(7,502,098)	$	(3,295,477)	$	(2,858,083)	$	(7,816,773)

Condensed Interim Consolidated Statements of Financial Position (Unaudited)
In Canadian dollars

(UNAUDITED)		September  30, 2018		December 31,  2017
ASSETS
Current
Cash and cash equivalents		$	75,282,348	$	4,522,644
Amounts receivable		2,699,574		1,429,123
Inventory		7,380,045		270,169
Biological assets		698,766		-
Prepaid and other assets		2,310,972		250,744
Advances and loans receivable - current		1,376,166		1,102,168
Asset held for sale		1,064,910		-
Convertible notes		-		373,127
		90,812,781		7,947,975
Non-Current
Deferred financing charges		1,561,852		-
Advances and loans receivable		-		66,421
Interest in equity accounted investees		2,734,811		3,596,333
Investments		6,852,062		17,243,342
Royalty investments		1,288,048		5,834,613
Property and equipment		11,143,101		1,084,098
Intangible assets		49,920,100		5,607,598
Goodwill		55,891,281		4,759,377
		129,391,255		38,191,782
Total Assets		$	220,204,036	$	46,139,757
LIABILITIES
Current
Amounts payable and accrued liabilities		$	12,579,989	$	1,606,689
Loans payable and other liabilities		13,184,582		425,345
Current tax liability		1,389,909		102,236
		27,154,480		2,134,270
Non-Current
Capital lease		261,551		-
Purchase consideration payable		2,136,274		-
Convertible debt		27,909,598		1,431,950
Line of credit		-		826,517
Deferred tax liability		15,521,588		1,278,676
Total Liabilities		72,983,491		5,671,413
SHAREHOLDERS' EQUITY
Share capital		$	105,823,518	$	50,007,891
Share subscription and contingent shares		48,002,790		-
Warrants reserve		4,590,904		4,149,703
Contributed surplus		15,280,457		9,902,292
Accumulated other comprehensive loss		(1,552,424)		(1,032,719)
Accumulated deficit		(25,099,602)		(22,381,817)
Non-controlling interest		174,902		(177,006)
Shareholders' Equity		147,220,545		40,468,344
Total Liabilities & Shareholders' Equity		$	220,204,036	$	46,139,757

Condensed Interim Consolidated Statements of Cash Flows (Unaudited)
In Canadian dollars

(UNAUDITED)		Nine months ended September 30
		2018		2017
CASH FLOWS USED IN OPERATING ACTIVITIES
Net income (loss) for the period		$	(2,858,083)	$	(7,816,773)
Items not affecting cash:
Bad debt expense (recovery)		33,122		(7,268)
Income from equity accounted investees		(168,664)		(706,821)
Amortization of property and equipment		300,072		137,730
Amortization of intangibles		2,151,139		601,413
Amortization of royalties		820,553		411,145
Amortization of fees related to line of credit		611,631		68,469
Share based compensation		4,222,561		2,499,356
Consulting fees paid via issuance of shares		-		30,000
Transaction adjustment paid via issuance of shares		-		204,060
Deferred tax recovery		(446,764)		(230,702)
Recovery on impairment of convertible notes receivable		(4,100)		-
Loss related to change in fair value of embedded derivatives		-		369,036
Write-off of inventory, net of recoveries		12,267		-
Accretion of convertible debt		378,292		-
Gain on reclassification of assets held for sale		-		-
Gain on disposal of equipment		-		(91,674)
Realized fair value amounts of inventory sold		1,161,471		-
Unrealized fair value gain on growth of biological assets		(951,694)		-
Gain on settlement of interests at acquisition		(1,098,374)		-
Fair value gain on warrants		(104,344)		-
Gain on the sale of licensed technology		(4,196,477)		-
Gains on investments		(12,762,704)		-
		(12,900,096)		(4,532,029)
Changes in non-cash items relating to operations:
Increase in amounts receivable		(123,412)		(1,064,247)
Increase in inventory		(1,860,749)		(147,211)
Increase in prepaid and other assets		(1,224,839)		(156,794)
Increase (decrease) in accounts payable and accruals		1,863,400		(1,021,754)
Increase in biological assets		(259,917)		-
Increase in current tax liability		251,968		-
		(14,253,645)		(6,922,035)
CASH FLOWS FROM/(USED) IN INVESTING ACTIVITIES
Purchase of property and equipment		(6,811,821)		(151,861)
Purchase of Intangible assets		(54,924)		-
Payments for acquisitions, net of cash received		(1,074,056)		-
Proceeds from the sale of investments		28,139,404		-
Proceeds from the collection of convertible debt		392,100		-
Purchase of interests in equity accounted investments		-		(1,917,884)
Royalty financing arrangements		(1,265,000)		(3,962,131)
Loans advanced to debtors including issuance costs, net of repayment		(2,848,359)		(1,488,018)
		16,477,344		(7,519,894)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issued shares in bought deal financing, net of costs		12,015,990		10,958,243
Proceeds from issuance of convertible debt, net of costs		31,249,904		-
Proceeds from issuance of warrants, net of costs		3,628,950		2,787,000
Proceeds from exercise of warrants		11,665,043		404,592
Repayment of line of credit		(3,000,000)		-
Rapayment of loans		(71,467)		-
Proceeds from common and preferred shares issued to minority holders of Trichome		13,259,530		-
Proceeds from issuance of stock options		186,500		25,000
Payments related to share buyback bid		(98,382)		-
Tax withholding paid on exercise of restricted share units		-		(84,887)
		68,836,068		14,089,948
Effect of movement of exchange rates on cash held		(300,063)		-
INCREASE (DECREASE) IN CASH		$	70,759,704	$	(351,981)
CASH, BEGINNING OF PERIOD		4,522,644		2,945,895
CASH, END OF PERIOD		$	75,282,348	$	2,593,914

SOURCE Origin House

Marc Lustig, Chairman and CEO, [email protected], 1-844-556-5070, www.originhouse.com; Jonathan Ross, CFA, LodeRock Advisors Inc., [email protected], 416-283-0178